World's Best Scientists 2026 revealed!
Diane F. Jelinek

Diane F. Jelinek

D-Index & Metrics

Immunology

D-Index
84
Citations
20027
World Ranking
1408
National Ranking
717

Medicine

D-Index
84
Citations
20027
World Ranking
15315
National Ranking
7727

Overview

Diane F. Jelinek is affiliated with the Mayo Clinic in the United States and has a research focus primarily in the fields of medicine, immunology and microbiology, as well as biochemistry, genetics, and molecular biology. Their work spans several subfields including immunology, genetics, oncology, hematology, and pathology and forensic medicine.

The research topics covered by Diane F. Jelinek include:

  • Chronic Lymphocytic Leukemia Research
  • Immunodeficiency and Autoimmune Disorders
  • Lymphoma Diagnosis and Treatment
  • Multiple Myeloma Research and Treatments
  • Immune Cell Function and Interaction
  • Cancer-related molecular mechanisms research
  • Extracellular vesicles in disease

The scientist's recent publications illustrate a focus on hematologic malignancies and immune interactions. Selected papers include:

  • Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial, 2022, Blood
  • Targeting cancer-associated fibroblasts in the bone marrow prevents resistance to CART-cell therapy in multiple myeloma, 2022, Blood
  • Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL, 2020, Blood
  • B cell receptor signaling drives APOBEC3 expression via direct enhancer regulation in chronic lymphocytic leukemia B cells, 2022, Blood Cancer Journal
  • Stage-Specific Non-Coding RNA Expression Patterns during In Vitro Human B Cell Differentiation into Antibody Secreting Plasma Cells, 2022, Non-Coding RNA

Frequent publication venues for Diane F. Jelinek comprise Clinical Lymphoma Myeloma & Leukemia, Blood, Blood Cancer Journal, Blood Advances, and Non-Coding RNA.

The scientist has collaborated regularly with several researchers, including Renee C. Tschumper, Neil E. Kay, Denise K. Walters, Esteban Braggio, and Marta Chesi. These co-authors frequently appear across multiple publications, reflecting ongoing research partnerships.

Best Publications

  • Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma.

    Robert A. Kyle;Ellen D. Remstein;Terry M. Therneau;Angela Dispenzieri

  • Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia

    Tait D. Shanafelt;Xin V. Wang;Neil E. Kay;Curtis A. Hanson

  • Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival.

    Anne J. Novak;Anne J. Novak;Jaime R. Darce;Jaime R. Darce;Bonnie K. Arendt;Bonnie K. Arendt;Brandon Harder;Brandon Harder

  • Cloning and regulation of cholesterol 7 alpha-hydroxylase, the rate-limiting enzyme in bile acid biosynthesis.

    Diane F. Jelinek;Stefan Andersson;Clive A. Slaughter;David W. Russell

  • Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma

    Angela Dispenzieri;Robert A. Kyle;Jerry A. Katzmann;Terry M. Therneau

  • Comprehensive Assessment of Genetic and Molecular Features Predicting Outcome in Patients With Chronic Lymphocytic Leukemia: Results From the US Intergroup Phase III Trial E2997

    Michael R. Grever;David M. Lucas;Gordon W. Dewald;Donna S. Neuberg

  • Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia

    Neil E. Kay;Susan M. Geyer;Timothy G. Call;Tait D. Shanafelt

  • Regulated Expression of BAFF-Binding Receptors during Human B Cell Differentiation

    Jaime R. Darce;Bonnie K. Arendt;Xiaosheng Wu;Diane F. Jelinek

  • Prospective Evaluation of Clonal Evolution During Long-Term Follow-Up of Patients With Untreated Early-Stage Chronic Lymphocytic Leukemia

    Tait D. Shanafelt;Thomas E. Witzig;Stephanie R. Fink;Robert B. Jenkins

  • Chronic Lymphocytic Leukemia

    Neil E. Kay;Terry J. Hamblin;Diane F. Jelinek;Gordon W. Dewald

  • Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia

    Gordon W. Dewald;Stephanie R. Brockman;Sarah F. Paternoster;Nancy D. Bone

  • VEGF Receptor Phosphorylation Status and Apoptosis is Modulated by a Green Tea Component, Epigallocatechin-3-gallate (EGCG) in B cell Chronic Lymphocytic Leukemia

    Yean K. Lee;Nancy D. Bone;Ann K. Strege;Tait D. Shanafelt

  • Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial

    Unknown

  • Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival.

    Anne J. Novak;Richard J. Bram;Neil E. Kay;Diane F. Jelinek

  • Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia.

    Diane F. Jelinek;Renee C. Tschumper;Susan M. Geyer;Nancy D. Bone

  • Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome.

    Anne J. Novak;Deanna M. Grote;Mary Stenson;Steven C. Ziesmer

  • IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells

    Jun Won Lee;Ho Yeon Chung;Lori A. Ehrlich;Diane F. Jelinek

  • Phase I Trial of Daily Oral Polyphenon E in Patients With Asymptomatic Rai Stage 0 to II Chronic Lymphocytic Leukemia

    Tait D. Shanafelt;Tim G. Call;Clive S. Zent;Betsy LaPlant

  • Gene-expression profiling of Waldenström macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma

    Wee J. Chng;Roelandt F. Schop;Tammy Price-Troska;Irene Ghobrial

  • Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma.

    Stephen M. Ansell;Thomas E. Witzig;Paul J. Kurtin;Jeff A. Sloan

  • CD4+ T-Cell Immune Response to Large B-Cell Non-Hodgkin’s Lymphoma Predicts Patient Outcome

    Stephen Maxted Ansell;M. Stenson;Thomas Matthew Habermann;Diane F Jelinek

Frequent Co-Authors

Neil E. Kay
Neil E. Kay Mayo Clinic
Tait D. Shanafelt
Tait D. Shanafelt Stanford University
Curtis A. Hanson
Curtis A. Hanson Mayo Clinic
Susan L. Slager
Susan L. Slager Mayo Clinic
Thomas E. Witzig
Thomas E. Witzig Mayo Clinic
Gordon W. Dewald
Gordon W. Dewald Mayo Clinic
Paolo Ghia
Paolo Ghia Vita-Salute San Raffaele University
Šárka Pospíšilová
Šárka Pospíšilová Masaryk University
Rafael Fonseca
Rafael Fonseca Mayo Clinic

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, exploring related healthcare degrees can open diverse career opportunities. Nursing degrees, for instance, offer a strong foundation in patient care and biological sciences, which complement immunological knowledge.

If you’re transitioning into nursing from another field, programs like the best online bsn programs for non nurses provide flexible, reputable pathways. These programs are designed to accommodate non-traditional students and build essential nursing skills efficiently.

For faster entry into nursing, the easiest absn programs to get into offer accelerated formats with more straightforward admission requirements, ideal for those seeking to launch their nursing career quickly.

Entry-level nursing roles can be pursued via lpn programs with easiest admission requirements, which provide vital clinical experience and a gateway to advanced practice. These programs are accessible and can lead to impactful positions in healthcare settings.

For advanced practice roles, consider the easiest nurse practitioner program, allowing nurses to expand their scope of practice with a more manageable admission process. These programs are well-suited for immunology professionals aiming to influence patient outcomes through specialized knowledge.

Best Scientists Citing Diane F. Jelinek

Trending Scientists